MET and breast cancer: In breast cancer cells, hyperactivation of signaling pathways such as phosphoinositide 3-kinase–AKT– (PI3K/AKT/mTOR), MAPK, and hepatocyte growth factor (HGF)/Met (hepatocyte growth factor receptor (HGFR)) increases cell growth, proliferation, survival, and cancer hallmarks [76,77].